New designs of female condoms have been developed to lower cost and/or improve acceptability. To secure regulatory approvals, clinical studies are required to verify performance. We aimed to assess the functional performance and safety of two new female condom types — Velvet and Cupid2 female condom — against the existing FC2 female condom.
This was a three-period crossover, randomized noninferiority clinical trial with 300 women randomized to condom-type order in one South African site. Primary end points were total clinical failure and total female condom failure. Noninferiority of component modes, clinical breakage, nonclinical breakage, slippage, misdirection and invagination were also determined. Safety data were also assessed for each female condom. Participants were asked to use five of each female condom type and to collect information on use in a condom diary at home and were interviewed after use of each type. Frequencies and percentages were calculated by condom type for each failure mode, and differences in performance of the three female condoms using FC2 as reference, with 95% confidence intervals, were estimated using generalized estimating equation models.
A total of 282 (94%) participants completed follow-up, using at least one condom of each type. Total clinical failure (clinical breakage, invagination, misdirection, slippage) was <5% for all female condoms: FC2 (4.50%), Cupid2 (4.79%) and Velvet (3.93%). Noninferiority was demonstrated for all condom failure modes for the two new female condoms with respect to FC2, within the margin of 3% difference in mean failure, at the 5% significance level.
Noninferiority for the two new female condoms was demonstrated with respect to the marketed FC2. These data are used to support manufacturer dossiers for World Health Organization (WHO)/United Nations Population Fund (UNFPA) prequalification.
Data from this study have been submitted to WHO/UNFPA and will contribute to the prequalification submission requirements for the Cupid2 and Velvet female condoms.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- A review of the effectiveness and acceptability of the female condom for dual protection.Sex Health. 2012; 9: 18-26https://doi.org/10.1071/SH11037
- The Female Health Company Annual report 2013.[accessed Nov 17th 2014])
- HIV prevention gains momentum.978-0-89714-933-4 UNFPA, 2011
- Caucus on new and underused reproductive health technologies product brief: female condom.
- New female condoms in the pipeline.Reprod Health Matters. 2012; 20: 188-196https://doi.org/10.1016/S0968-8080(12)40659-0
- Performance of the Reality® polyurethane female condom and a synthetic latex prototype: a randomised cross-over trial among South African women.Contraception. 2006; 73: 386-393
- Performance and safety of the second-generation female condom versus the Woman’s, the VA worn-of-women, and the Cupid female condoms: a randomised controlled non-inferiority crossover trial.Lancet Glob Health. 2013; 1: e146-e152https://doi.org/10.1016/S2214-109X(13)70054-8
- Female condoms — requirements and test methods.[accessed July 6, 2012])
- Standardized definitions of failure modes for female condoms.Contraception. 2007; 75: 251-255
- Experimental designs balanced for the estimation of residual effects of treatments.Aust J Sci Res. 1949; 2: 149-168
- Stata Statistical Software: Release 13.StataCorp LP.STATA, College Station, TX2013
- Using scratch card technology for random allocation concealment.Clin Trials. 2012; 10 (): 125-130https://doi.org/10.1177/1740774512465496
- Comparative crossover study of the PATH Woman's Condom and the FC Female Condom®.Contraception. 2008; 78: 465-473https://doi.org/10.1016/j.contraception.2008.07.020
- Comparative acceptability study of the Reality female condom and version 4 of modified Reddy female condom in India.Contraception. 2005; 72: 366-371
- Three new female condoms: which do South African women prefer?.Contraception. 2011; 83: 248-254https://doi.org/10.1016/j.contraception.2010.08.002
- Issues in the design, analysis and interpretation of condom functionality studies.Contraception. 2009; 80: 237-244
- Systematic Review of Contraceptive Medicines. “Does choice make a difference?”.
- Fertility reduction and the quality of family planning services.Stud Fam Plann. 1989; 20: 1-16
- [accessed 18th April 2015])
Published online: May 19, 2015
Accepted: May 14, 2015
Received in revised form: May 1, 2015
Received: February 2, 2015
☆There are no conflicts of interest known to the authors.
☆☆This study was funded by the Universal Access to Female Condoms Joint Programme, The William and Flora Hewlett Foundation, and Cupid Ltd.
★This trial is registered on the South African Clinical Trials database DOH-27-0113-4272.
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.